Latest filing published 06 May 2026 for 한올바이오파마, €183k.
Filing timeline
BuySaleInsider track record
No signal scores available.
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- +0.9%Entry ₩44,350 · Close 08 Oct 2026 ₩44,750
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
박승국: trading record in brief
박승국, listed as chief executive, appears in our data through filings on 한올바이오파마 shares, published by DART (FSS). We count 4 filings; the first trade dates from 4 June 2024 and the latest from 6 May 2026.
Purchases make up the whole of the open-market record (4 purchases, €183k). No amount is published for 3 filings, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. In 2026 alone, the filings show 1 purchase and no sales.
Most recently, on 6 May 2026, the filings show an open-market purchase worth €183k in 한올바이오파마. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.
Companies and markets linked to 박승국
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 13,334 shares@ ₩23,363.000.0100% mcap100.0% of flowShareKRXDART:20260506000621Canonical exit: 4 Aug 2026 (T+90)
- 13,333 sharesShareKRXDART:20250430001334Canonical exit: 29 Jul 2025 (T+90)
- ShareKRXDART:20241106000204Canonical exit: 28 Jan 2025 (T+90)
- ShareKRXDART:20240604000257Canonical exit: 2 Sept 2024 (T+90)
4 of 4 declarations